SLIL Biomedical has filed an Investigational New Drug application in theUSA for its lead candidate drug, SL11047 for the treatment of AIDS-related lymphoma, seeking approval to start a Phase I/II trial to assess tolerability to increasing doses in ARL patients.
SL11047 is a new-generation polyamine analog which is thought to act by attaching to DNA and preventing cells from dividing. First-generation drugs of this kind were limited by toxicity concerns, but SLIL's president and chief executive, Peter Molloy, says that the company "now has other second- and third-generation polyamine compounds," and a pipeline of more than a dozen lead compounds. Its second candidate drug, SL11093, is in preclinical development for prostate cancer.
SLIL says that if SL11047 proves to be well-tolerated and effective in the treatment of ARL, it will seek fast-track US Food and Drug Administration review with a view to launching the drug in 2004.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze